Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Intangibles of $592.8 million for Q4 2025, up 117.84% year-over-year from $272.1 million in Q4 2024, and up 117.84% quarter-over-quarter from $272.1 million in Q4 2024.
Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Intangibles for 3 consecutive years, with $592.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Intangibles rose 117.84% year-over-year to $592.8 million; the TTM figure through Dec 2025 stood at $592.8 million (up 117.84% YoY), while the FY2025 annual figure was $592.8 million, up 129.9% from the prior year.
- Intangibles advanced to $592.8 million in Q4 2025 per TLX's latest filing, from $272.1 million in the prior quarter.
- Across five years, Intangibles topped out at $592.8 million in Q4 2025 and bottomed at $71.4 million in Q4 2023.
- Historically, Intangibles has averaged $312.1 million across 3 years, with a median of $272.1 million in 2024.
- Annual changes were most pronounced in 2024 — Intangibles surged 281.2% — and 2025, when it surged 117.84%.
- Telix Pharmaceuticals' Intangibles stood at $71.4 million in 2023, then soared by 281.2% to $272.1 million in 2024, then soared by 117.84% to $592.8 million in 2025.
- Business Quant data shows TLX's Intangibles at $592.8 million in Q4 2025, $272.1 million in Q4 2024, and $71.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 592.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 592.82 Mn |
| Dec 31, 2024 | 272.13 Mn |
| Dec 31, 2023 | 71.39 Mn |